Novel hydrazone-isatin derivatives as potential EGFR inhibitors: Synthesis and in vitro pharmacological profiling.

Ahmed, Marwa F; El-Haggar, Radwan; Almalki, Atiah H; Abdullah, Omeima; El Hassab, Mahmoud A; Masurier, Nicolas; Hammad, Sherif F

Ahmed, Marwa F; El-Haggar, Radwan; Almalki, Atiah H; Abdullah, Omeima; El Hassab, Mahmoud A; Masurier, Nicolas; Hammad, Sherif F.

Afiliación

Ahmed MF; Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia.
El-Haggar R; Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Ain Helwan, Egypt.
Almalki AH; Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Abdullah O; Addition and Neuroscience Research Unit, College of Pharmacy, Taif University, Taif, Al-Hawiah, Saudi Arabia.
El Hassab MA; Pharmaceutical Chemistry Department, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Masurier N; Department of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, Egypt.
Hammad SF; Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, CNRS, Université de Montpellier, ENSCM, Montpellier, France.

Arch Pharm (Weinheim) ; 356(9): e2300244, 2023 Sep.

Article en En | MEDLINE | ID: mdl-37404064

Palabras clave

EGFR; anticancer; breast cancer; hydrazone; isatin

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Arch Pharm (Weinheim) Año: 2023 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: Alemania

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google